• A comprehensive oncologic imaging is achieved with PET/MRI when an appropriate protocol is used.
Introduction
Hybrid positron emission tomography/magnetic resonance imaging (PET/MRI) scanners have the potential to become an effective tool for the evaluation of oncology patients before, during, and after treatment and can influence patient management [1, 2] . Hybrid PET/MRI uses PET data to assess the metabolic information of malignant tumors and relies on the uptake of radiotracers. However, certain tumors such as mucinous carcinoma or signet cell-type adenocarcinoma may not reveal the uptake of fluorodeoxyglucose (FDG), which is the most commonly used radiotracer. On the other hand, the physiological uptake of FDG in the liver and brain may prevent the depiction of tumors. Therefore, MRI data collected from hybrid PET/MRI systems not only provide superior soft tissue contrast and anatomic detail but may also improve the evaluation of malignant tumors. Therefore, the choice of imaging protocol is crucial for increasing the sensitivity of MRI. The use of intravenous contrast media is essential to oncologic imaging, especially for the detection of malignant tumors in the brain and in the upper abdomen [3] [4] [5] . In this study, we investigated whether contrast-enhanced (CE) whole-body PET/MRI protocols increase the sensitivity of detection of malignant tumors compared to non-CE (NCE) protocols.
Subjects and Methods
In our study, 93 consecutive patients with histopathologically proven primary malignant tumors aged between 20 and 87 were retrospectively evaluated (mean age ± SD, 55.1 ± 14.1 years) during the period of August 2015 to January 2018. Fifty-four of these patients were men (53.4 ± 14.7 years), and 39 of them were women (56.4 ± 13.6 years). The institutional review board approved the study; the requirement of informed consent was waived, since the study was a retrospective investigation. The patients referred to PET/MRI from the hematology/oncology and surgery departments as part of the standard oncology imaging were included in the study. Patients with a history of allergy to gadolinium-based contrast agents and end-stage renal failure were excluded from the study. All patients had histopathological proof of their primary malignant tumors by surgery (n = 56) and/or biopsy (n = 37).
Metastatic lesions without histopathologic evidence were identified based on the progression of their size or the appearance of new lesions during follow-up. The malignancy of the lymph nodes was determined based on their size and/or FDG uptake.
Eight patients underwent neoadjuvant therapy, and PET/MRI was performed at follow-up; 45 patients had their primary tumor surgically removed, followed by adjuvant chemotherapy and/or chemoradiotherapy. In 40 patients, the primary tumor was not deemed operable according to the criteria of other imaging modalities, and these patients either underwent chemotherapy and/or chemoradiotherapy.
All patients fasted for at least 6 h before imaging. The blood glucose level was assessed with a blood glucose meter (OneTouch Vita; LifeScan, Milpitas, CA, USA) before imaging to ensure that it was < 140 mg/dL (7.77 mmol/L).
PET/MRI was performed 45 ± 10 min after the injection of FDG (mean dose, 4.54 MBq per kilogram of body weight ±1; range, 370-400 MBq). The images were acquired in supine position on a 3 Tesla Biograph mMR scanner (Siemens Healthcare, Erlangen, Germany) using a 16-channel head and neck surface coil and three 12-channel body coils. These body coils were combined to form a multichannel whole-body coil by using the total imaging matrix technology. The whole-body images were obtained in 5 to 6 bed positions according to the size of the patient and each bed time position was maintained between 2 and 2.5 min. PET acquisition occurred simultaneously during the whole-body MRI acquisition. In all patients, the whole-body PET/MRI covered the entire body from head to knee. For the attenuation correction, 4-point Dixon images were obtained in the coronal plane. The whole-body MRI protocol consisted of both NCE images and CE images and provided the most comprehensive oncologic imaging dataset in the routine in our institution. The imaging stations were arranged consecutively in the caudocranial direction. The comprehensive MRI protocol that included both CE and NCE studies consisted of T2-weighted single-shot echo train (HASTE; TR/TE, 1,500 ms/87 ms) in the coronal plane, T1-weighted slice-selective Turbo Flash (TR/TE, 1,600 ms/2.5 ms), and free breath diffusion-weighted imaging (DWI) using EPI technique (TR/TE, 12,000 ms/78 ms, b = 0 and 800 s/mm 2 ) in the axial planes. After the NCE protocol was performed, a weight-adapted dose of a gadolinium-based contrast agent was administered, and serial CE images were obtained using breath-hold 3D VIBE (TR/TE, 4.56 ms/2.03 ms) in the arterial, portal venous and equilibrium phases covering the upper abdomen in the axial plane. After the serial CE images were acquired, continuous breath-hold 3D VIBE images were obtained from head to knee in the axial plane, and all the sections were combined, resulting in uninterrupted whole-body coverage. Detailed information regarding the whole-body PET/MRI protocol is shown in Table 1 . The total scan duration of the PET/MRI examination was 50-60 min. The durations of both the NCE and CE protocols were 25-30 min.
The images were evaluated by 2 radiologists; one had 25 years of experience, and the other had 8 years of experience in reading MRI and hybrid imaging. Both readers were blinded to patient data and diagnosis. One research associate separated each study into 2 parts, and the loaded images had an NCE part and a CE part. Data were analyzed on a dedicated workstation (Syngo Via; Siemens Healthcare, Erlangen, Germany). The NCE and CE protocols were reviewed 1 month apart to avoid bias. The review of the cases for CE and NCE studies took 1 h each. All images with diagnostic quality for PET and MRI were evaluated separately and as fused images, the number of lesions was recorded for both protocols. The radiologists and a nuclear medicine physician evaluated the images in a joint reading session and made consensus. The NCE dataset was evaluated using NCE MR images, PET/MRI fusion images, and attenuation-corrected raw data PET images. The CE dataset was evaluated by reviewing CE MR images, fused PET/MRI images, and attenuation-corrected raw data PET images.
Statistical analyses were performed using SPSS software version 20. The variables were investigated using visual methods (histograms, probability plots) and analytical methods (Kolmogorov-Smirnov) to determine whether or not the distribution was normal.
As most of the variables excepting "age" were not represented by real numbers, descriptive analyses for tests were presented using medians and interquartile range (IQR). Friedman's test was conducted to evaluate whether there is a significant change in the total number of detected lesions among different MRI sequences separately for each anatomic region (due to violations of parametric test assumptions as number of lesions detected can only be integer). Pairwise comparisons were performed using Wilcoxon signed rank test. A p value of ≤0.05 was accepted as statistically significant.
Results
Of the 93 patients, 17 patients had non FDG-avid malignant tumors. The rest of the patients had FDG avid malignant tumors, 36 patients had distance metastasis (M), and 40 patients had lymph node metastases (N).
Distribution of the primary malignant tumors is shown in Table 2 . Gastrointestinal tumors include gastric, pancreatic, colorectal cancers, hepatocellular carcinoma, and cholangiocarcinoma.
The number of lesions detected using the CE protocol (median 2, IQR 0-14) was significantly higher than that detected using the NCE protocol (median 1, IQR 0-5; p < 0.001). The total number of lesions detected using the CE protocol varied between 0 and 120 (minimum-maximum), whereas that detected using the NCE protocol was 0-75 (minimum-maximum). The total number of lesions detected with only the PET component (median 1, IQR 0-11) was significantly lower than the number of lesions detected with the CE PET/MR protocol (median 2, IQR 0-14; p < 0.001).
Regarding the number of region-based lesions, the number of lesions in the brain detected with the CE pro- tocol (median 2, IQR 1-2) was significantly higher than that detected with the NCE protocol (median 0, IQR 0-1; p = 0.001, n = 11; Fig. 1 ).
In the abdomen, the CE PET/MRI protocol (median 2, IQR 1-6) was superior to the NCE protocol (median1, IQR 0-2; p < 0.001, n = 65; Fig. 2 ).
There was no difference between the number of malignant tumors detected by the 2 protocols for the head and neck (p = 0.356, n = 13), bone (p = 0.414, n = 28), thorax (p = 0.09, n = 31; Fig. 3) , and lymph nodes (p = 0.196, n = 32; Table 3 ).
Discussion
Our study showed that the CE fast PET/MRI protocol depicted more malignant tumors in the upper abdomen and in the brain compared to the NCE protocol. In addition, our CE fast protocol may increase patient comfort due to its short duration and is an effective tool for the evaluation of oncology patients before, during, and after treatment.
PET/MRI is a new imaging modality that combines the sensitivity of molecular imaging of PET and the superior radiologic diagnostic capabilities of MRI. In addition, PET/MRI provides detailed background anatomical landmarks from MRI images. MRI also bestows superior tissue contrast that helps to localize tumors and assist in the local staging (T staging) of tumors. PET/MR is superior to PET/CT because its resolves soft tissue without the need for radiation exposure. The metabolic information from PET data together with the diagnostic accuracy of CE whole-body MRI may increase the sensitivity of tumor detection. Several studies have shown that the detection of primary and metastatic liver and brain tumors by MRI is superior to that by PET [3, 5] . In liver imaging, serial CE images are essential to depict hypervascular lesions, and only CE images can depict brain metastases [3, 4, [6] [7] [8] [9] . In the pancreas, CE images may depict hypervascular neuroendocrine tumors that are not FDG avid [10] [11] [12] . Additionally, renal tumors may be evaluated with CE images to differentiate between benign and malignant lesions [13] . PET images rely on the uptake of FDG, which is taken up physiologically by the tissues of the liver and brain. Primary liver tumors such as HCC can only take up FDG if they are less differentiated [14, 15] . In our dataset, CE PET/MRI depicted more HCC with the serial CE images. HCC is a hypervascular tumor with arterial blood supply, and arterial enhancement with venous washout is diagnostic for HCC in serial CE images [8] .
In contrast to our results, Lee at al. [16] presented that the effect of gadolinium-based contrast agents on PET image can be negligible quantitatively and qualitatively. In imaging renal and bladder tumors, MRI is superior to PET with CE protocols. Renal lesions, including cysts, can only be categorized according to their enhancement pattern [17] . In our dataset, we did not observe any primary renal tumor; however, CE MRI protocols can further help to distinguish between malignant and benign renal lesions. We did not observe any significant difference in bone metastasis and lymph node involvement.
FDG-PET detection of hypometabolic metastasis and increased bone marrow activity after chemotherapy is not sensitive [18] [19] [20] . Bone marrow-sensitive MRI techniques can provide diagnostic information on FDG-negative cases [21] . Our data showed that the combined evaluation of PET and MRI with either DWI or post-contrast VIBE equally assessed the bone marrow metastases. Previous studies have shown that CE MRI and DWI have similar sensitivities for the detection of bone metastases [22, 23] .
Stolzman et al. [24] and Catalano et al. [25] compared lung nodule detection rates using CT, MR, and PET either in different combinations or separately. They found similar detection rates for both PET/CT and PET/MRI. Our study revealed similar results for the detection of lung nodules. The duration of the whole-body PET/MRI examination is long, and it is unpleasant for the patient to undergo a 1-h examination in a closed environment. Therefore, shorter protocols have been performed [26, 27] . Our CE protocol may be used as a standard protocol for shorter examinations, which may increase patient throughput and patient comfort.
The limitation of our study may include the limited number of cases of each malignancy group and see which particular malignancy may benefit the most for CE protocol. Also, not all cases were histopathologically proven. Further prospective studies may be needed for tailored PET/MRI protocols for specific malignancies especially in terms of local staging. CE studies may be performed with the use of improved temporal resolution to calculate the contrast passage (Ktrans) and monitor the antiangiogenic treatments.
Conclusion
An optimal oncologic imaging was achieved using the appropriate protocol for PET/MRI, and a variety of tumor types and involvement of the organ systems can be reviewed by optimizing the protocol. We investigated the use of the CE whole-body PET/MRI protocol for the assessment of malignant tumors, and our results indicated that MRI with intravenous contrast might increase the sensitivity of PET/MRI. The protocol with the emphasis of CE examination can further shorten the PET/MRI exam with increased detection rate of neoplasms.
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